An FDA advisory committee is reviewing Moderna’s mRNA-based influenza vaccine, called mFlusiva (also reported as mFlusvia), as the agency considers whether to approve it for adults aged 50 and older. The review is taking place ahead of the upcoming winter flu season and represents a step in the FDA’s process toward a potential final decision. Multiple outlets describe the vaccine as the first flu shot built using the same mRNA technology that was used in COVID-19 vaccines.
Reports say Moderna is seeking approval for use in the older age group, and the advisory meeting focuses on the vaccine’s evidence from clinical testing and how it should be evaluated for that population. One outlet also reports that advanced trial results show the vaccine is more effective than a standard flu shot, while others characterize the meeting primarily as the assessment stage that could lead to an FDA decision.
Overall, the coverage agrees the committee’s discussion is a key milestone, with the goal of determining whether mRNA flu vaccination for older Americans should become an available option.
